SCHEMBL6632034

SCHEMBL6632034

O=COC1(Cc2ccccc2)CCCC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.49
CTSL P07711 4/20 0.49
CTSB P07858 3/20 0.49
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
KMT2A Q03164 1/20 0.38
CTSS P25774 1/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ADRB2 P07550 2/20 0.36
ALDH1A1 P00352 1/20 0.36
AKR1C1 Q04828 1/20 0.36
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH7 P40394 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7648047 0.96 CTSK (0.49) CTSKCTSLCTSBMAOAMAOB
SCHEMBL11823681 0.80 MAOA (0.48) CTSKCTSLCTSBMAOAMAOB
SCHEMBL6631739 0.80 ALDH1A1 (0.41) KMT2AHTTALDH1A1
SCHEMBL8767085 0.79 MAOA (0.47) CTSKCTSLCTSBMAOAMAOB
SCHEMBL6627421 0.78 TSHR (0.42) CTSKCTSLCTSBALDH1A1
SCHEMBL20959847 0.77 CTSK (0.52) CTSKCTSLCTSBCTSSLMNA
SCHEMBL16601016 0.77 MAOA (0.45) CTSKCTSLCTSBMAOAMAOB
SCHEMBL7531427 0.76 CTSK (0.50) CTSKCTSLCTSBMAOAMAOB
SCHEMBL28548895 0.76 CTSK (0.47) CTSKCTSLCTSBMAOAMAOB
SCHEMBL18727495 0.76 MAOA (0.44) CTSKCTSLCTSBMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040210051-A1 N-alkanoylphenylalanine derivatives CHEN LI (US) 2004-10-21 US disclosed
US-6806365-B2 ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4. HOFFMANN-LA ROCHER INC. 2004-10-19 US disclosed
EP-1005446-B1 N-AROYLPHENYLALANINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-02-25 EP disclosed
US-20030109459-A1 N-alkanoylphenylalamine derivatives CHEN LI (US) 2003-06-12 US disclosed
US-6455550-B1 INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-09-24 US disclosed
EP-1005446-A1 N-AROYLPHENYLALANINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-07 EP disclosed
WO-1999010313-A1 N-AROYLPHENYLALANINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109459-A1 N-alkanoylphenylalamine derivatives VCAM1, ICAM1, SELL CTSK 3387/4885CTSL 2203/4885CTSB 3126/4885
US-20040210051-A1 N-alkanoylphenylalanine derivatives VCAM1, ICAM1, CD59 CTSK 3267/4885CTSL 1488/4885CTSB 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.